Ignite Creation Date:
2024-05-06 @ 7:41 PM
Last Modification Date:
2024-10-26 @ 3:11 PM
Study NCT ID:
NCT06092086
Status:
RECRUITING
Last Update Posted:
2023-10-23
First Post:
2023-07-21
Brief Title:
Lorlatinib as the First-line Treatment in China Advanced ALK NSCLC
Sponsor:
Organization:
Guangdong Association of Clinical Trials